- Moskvitina EA, Mazrukho AB, Adamenko OL et al. [Characteristics of the epidemiological situation on cholera the world over.] Problems Part Danger Dis2013;1: 11–17.Russian.
- Onishchenko GG. [Infectious diseases in natural reservoirs: epidemic situation and morbidity in the Russian Federation and prophylactic measures.] Zh Mikrobiol Epidemiol Immunobiol2001;3: 22–28.Russian.
- Revich B, Tokarevich N, Parkinson AJ.Climate change and zoonotic infections in the Russian Arctic. Int J Circumpolar Health2012;71: 18792.
- Aikimbajev A, Meka-Mechenko T, Temiralieva G et al.Plague in Kazakhstan at the present time. Przegl Epidemiol2003;57: 593–598.
- Fetherston JD, Perry RD.The pigmentation locus of Yersinia pestis KIM6+ is flanked by an insertion sequence and includes the structural genes for pesticin sensitivity and HMWP2. Mol Microbiol1994;13: 697–708.
- Kutyrev VV, Eroshenko GA, Kukleva LM et al. [Comparative genetic characteristic of vaccine strain of Yersinia pestis EV and its putative ‘virulent derivatives’.] Zh Mikrobiol Epidemiol Immunobiol2009;3: 50–56.Russian.
- Meyer KF.Effectiveness of live or killed plague vaccines in man. Bull World Health Organ1970;42: 653–666.
- Saltykova RA, Faibich MM. [Experience from a 30-year study of the stability of the properties of the plague vaccine strain EV in the USSR.] Zh Mikrobiol Epidemiol Immunobiol1975;6: 3–8.Russian.
- Feodorova VA, Motin VL.Plague vaccines: current developments and future perspectives. Emerg Microbes Infect2012;1: e36.
- Feodorova VA, Motin VL.Plague vaccines.In: Feodorova VA, Motin VL (eds.) Vaccines against bacterial biothreat pathogens.Kerala: Research Signpost, 2011: 176–233.
- Girard G. [Vaccination de l’homme contre la peste au moyen de germes vivants (virus vaccin EV). Premiers resultates acquis a Madagascar.] Bull Acad Med1935;114: 16–23.French.
- Aleksandrov NI, Gefen NE, Gapochko KG et al. [Aerosol immunization with dry pulverized anatoxins and vaccines. VIII. Studies on a method of aerosol immunization with pulverized anti-plague vaccine of large numbers of men.] Zh Mikrobiol Epidemiol Immunobiol1962;33: 46–50.Russian.
- Stepanov AV, Marinin LI, Vorob’ev AA. [Aerosol vaccination against dangerous infectious diseases.] Vestn Ross Akad Med Nauk1999;8: 47–54.Russian.
- Akimovich VV, Shanina LN.Yersinia pestis strains that does not produce capsular antigen. Problems Microbiol Lab Diagn EDD Saratov1965;54–58.Russian.
- Shlyakhov EN, Rubinstein E.Human live anthrax vaccine in the former USSR. Vaccine1994;12: 727–730.
- Ginsburg NN. Live vaccines. History, elements of the theory, and practice.Moscow: Medicina, 1969.
- Keim P, Price LB, Klevytska AM et al.Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within Bacillus anthracis. J Bacteriol2000;182: 2928–2936.
- Aleksandrov NI, Gefen NE, Gapochko KG et al. [Aerosol immunization with dried live vaccines and toxoids. VI. A study of postvaccination reactions and immunological efficacy of aerosol immunization with aerosol brucellosis, tularemia, anthrax and plague vaccines in man.] Zh Mikrobiol Epidemiol Immunobiol1961;32: 1245–1252.
- Sadovoi NV, Kravets ID, Selivanenko GM. [Vaccine anthrax combined.] Patent Russian Federation No. 2115433 (08.28.1992). Russian.
- The All-Russian State Center for Quality and Standardization of Veterinary Drugs and Feed (VGNKI). Catalog cultures of the Russian State Collection of Microorganisms.Moscow: VGNKI, 2010.Available at http://www.vgnki.ru/structure/subdivisions/otdelenie_biologicheskih_lekarstvennyh_sredstv_i_biotehnologii/collection_of_microorganisms/katalog/shtammy_bakterij_1_chast/ (accessed 30 August 2010).
- Ellis J, Oyston PC, Green M et al.Tularemia. Clin Microbiol Rev2002;15: 631–646.
- Elbert BJ, Gaiski NA. [On the mechanic of infection and immunity in experimental tularemia.] Zh Mikrobiol Epidemiol Immunobiol1945;7–8: 55–56.Russian.
- Olsufiev NG, Rudnev GP. Tularemia.Moscow: Medgiz, 1960.
- Sjostedt A, Tarnvik A, Sandstrom G.Francisella tularensis: host–parasite interaction. FEMS Immunol Med Microbiol1996;13: 181–184.
- Eaves-Pyles T.The progress and promise of new tularemia vaccines.In: Feodorova VA, Motin VL (eds.) Vaccines against bacterial biothreat pathogens.Kerala: Research Signpost, 2011: 235–258.
- Firstova VV, Kravchenko TB, Zyrina EB et al. [Evaluation of T-cell and humoral post-vaccinal specific immunity in humans who are regularly vaccinated against tularemia on prophylactic reason.] Life Without Danger2012;2: 96–102.Russian.
- Dzhaparidze MN, Nikitina GP, Kulikova VL et al. [Choleragen-anatoxin chemical cholera vaccine enriched with Ogawa O-antigen]. Zh Mikrobiol Epidemiol Immunobiol1984;4: 70–74.Russian.
- Sumarokov AA, Ivanov NR, Dzhaparidze MN et al. [The determination of the optimal inoculation dose of an oral cholera chemical bivalent vaccine in a controlled experiment.] Zh Mikrobiol Epidemiol Immunobiol1990;12: 55–62.Russian.
- Sumarokov AA, Dzhaparidze MN, Eliseev IuIu et al. [The determination of the optimal inoculation dose of an oral cholera bivalent chemical vaccine in a controlled trial of the vaccination of children and adolescents.] Zh Mikrobiol Epidemiol Immunobiol1993;5: 55–60.Russian.
- Sumarokov AA, Ivanov NR, Lelikov VL et al. [Reactogenicity and immunological effectiveness of an oral cholera chemical vaccine in a limited controlled experiment with human revaccination.] Zh Mikrobiol Epidemiol Immunobiol1978;12: 87–92.Russian.
- Dzhaparidze MN, Egorova VD, Karaeva LT et al. [A study of immunological efficacy of the oral chemical cholera vaccine on experimental animals.] Zh Mikrobiol Epidemiol Immunobiol1976;11: 115–119.Russian.
- Kamzolkina NB, Karaeva LT, Dzhaparidze MN. [Serologic interrelations of choleragen and the neurotoxins of enterobacteria.] Zh Mikrobiol Epidemiol Immunobiol1975;12: 50–54.Russian.
- Fedorova VA, Syrova NA, Gromova OV et al. [Synthesis of protective antigens during submerged cultivation of Vibrio cholerae.] Zh Mikrobiol Epidemiol Immunobiol2000;6: 72–74.Russian.
- Fyodorova VA, Syrova NA, Gromova OV et al. [The use of dot immunoassay in the control of the synthesis of immunogens during the production of anti-cholerae chemical oral vaccine.] Biotechnology2000;4: 87–94.Russian.
- Naumov AV, Popova AE, Anisimova TI et al.Method for protection of livestock from colibacteriosis and salmonellosis.Patent RF No. 2020958.Moscow: Ruspatent, 1994.Available at http://www.findpatent.ru/patent/202/2020958.html (accessed 10 February 2004).
- Kovtun AL, Darmov IV, Bogatcheva NV et al. [Glanders vaccine: development, clinical trials, and recommendation for the use.] Epidemiol Vaccin Prev2006;4: 39–46.Russian.
- Manzeniuk IN, Ganina EA, Dorokhin VV et al. [Burkholderia mallei and Burkholderia pseudomallei. Study of immuno- and pathogenesis of glanders and melioidosis. Heterologous vaccines.] Antibiot Khimioter1999;44: 21–26.Russian.
- Khomiakov IuN, Manzeniuk IN, Naumov DV et al. [The principles of the therapy of glanders in monkeys.] Zh Mikrobiol Epidemiol Immunobiol1998;1: 70–74.Russian.
- Vershilova PA, Golubeva AA, Kaitmazova EI et al.Brucellosis.Moscow: Medgiz, 1961.Russian.
- Corbel MJ, Feodorova VA.Vaccines against human brucellosis.In: Feodorova VA, Motin VL (eds.) Vaccines against bacterial biothreat pathogens.Kerala: Research Signpost, 2011: 59–92.
- Sumarokov AA, Karinskaia GA, Dranovskaia EA et al. [Comparative study of the safety, reactogenicity and antigenic activity of chemical and live brucellosis vaccines in a controlled epidemiological trial.] Zh Mikrobiol Epidemiol Immunobiol1984;2: 58–63.Russian.
- Vershilova PA, Dranovskaia EA, Karinskaia GA et al. [Determination of the optimal inoculation dose of Brucella chemical vaccine.] Zh Mikrobiol Epidemiol Immunobiol1982;10: 59–65.Russian.
- Kulakov YK, Zheludkov MM, Sclyarov OD.Variable-number tandem repeat markers for identification of Brucella abortus 82 and 75/79-AV vaccine strains.Vaccine 2010;28 Suppl 5: F41–F45.
- Pashaeva SA. [Therapeutic brucellosis vaccine for an immunotherapy the patients with chronic brucellosis.] Proceeding of the 2nd Intern Conference dedicated to the 100th Anniversary of Perm Company “Biomed”, 1–3 March, 1998;Perm, Russia. BioMed Press, Perm, Russia, 1998, pp57–58.Russian.
- Shabalin BA, Okhapkina VYu, Gavrilova LB. [Combined brucеllosis therapy with antibacterial preparations and therapeutic brucellosis vaccine.] Chem Biol Saf2007;2–3: 42–48.Russian.
- Ostrovsky N.Brucellosis.Yushchuk ND, M. Vengerov YY, (eds.) Brucellosis—lectures on infectious diseases.Columbus, OH: JSC ‘Publisher’ Medicine, 2007: 413–427.Russian.
- Konyushkova AN, Savchenko AY, Davydova KS, Ramenskaya GV, Kukes VG. [Overview of requirements for bioequivalence studies of generics. Requirements FDA.] Remedium2011;5: 54–56.Russian.
- Saltykov RA, Motornaia VP, Sirotiuk LV. [Experience of a 25-year study of the stability of properties of tularemia vaccine strains.] Zh Mikrobiol Epidemiol Immunobiol1972;49: 64–70.Russian.
- Onishchenko GG, Lazikova GF. [Legal basis of vaccine prophylaxis in Russia.] Zh Mikrobiol1998;6: 46–48.Russian.
- Onishchenko GG. [Actual problems of infectious diseases prevention at present time.] Zh Mikrobiol Epidemiol Immunobiol2010;4: 13–22.Russian.
- Feodorova VA, Corbel MJ.Prospects for new plague vaccines. Expert Rev Vaccines2009;8: 1721–1738.
- Feodorova VA, Ulyanova OV.Development of diagnostic kits and vaccines for bacterial infections.In: Georgiev VS, Western KA, McGowan JJ (eds.) National Institute of Allergy and Infectious Diseases, NIH, Vol 1: Frontiers in Research.Totowa: Humana Press, 2008: 241–248.
- Dentovskaia SV, Kopylov PKh, Ivanov SA et al. [A molecular basis of the plague vaccine development.] Mol Gen Mikrobiol Virusol2013;3: 3–12.Russian.
- Dalvadyants SM. [Characteristics of somatic antigen isolated from avirulent, non-capsular and non-toxic strains of Y. pestis using the method of Boivin.] Problems Part Danger Dis (Saratov)1968;2: 134–138.Russian.
- Dalvadyants SM, Dyatlov IA, Yeremin SA et al. [Plague immunization studies. Communication 4. An experience of volunteer revaccination with the ‘chemical’ and live plague vaccines.] Problems Part Danger Dis (Saratov)2006;1: 57–62.Russian.
- Byvalov AA, Yevstigneev VI, Darmov IV et al. [Antigenic composition of plague chemical vaccine.] Patent Russian Federation No. 2190424 (07.18.2001).Russian.
- Feodorova VA, Devdariani ZL.Immunogeneity and structural organisation of some pLCR-encoded proteins of Yersinia pestis. J Med Microbiol2001;50: 13–22.
- Feodorova VA, Devdariani ZL. [Prospects for experimental anti-idiotype vaccine against plague.] Immunology2006;3: 144–148.Russian.
- Feodorova VA, Devdariani ZL, Nazarova LS.Adjuvant effect of anti-idiotypic antibodies to Yersinia pestis lipopolysaccharide. J Med Microbiol1999;48: 751–756.
- Kogotkova OI, Overchenko VV, Efremenko VI et al. [Increase in efficacy of antibiotic therapy of anthrax under experimental conditions.] Antibiot Khimioter2002;47: 27–30.Russian.
- Taran TV. Development of conditions for drugs and immunogenic liposomal formulations that can be used for the treatment of experimental extremely dangerous infections as immunotherapeutic agents.DSc thesis, Stavropol API, Stavropol, Russia, 2004.
- Smirnova NI, Krepostnova IM, Livanova LF. [An avirulent Vibrio cholerae strain-producer of the cholera toxin B subunit: obtaining and molecular genetic analysis.] Mol Gen Mikrobiol Virusol2007;4: 7–13.Russian.
- Smirnova NI, Livanova LF, Chekhovskaia GV et al. [Strains of Vibrio cholerae serogroups O1 and O139 that produce the basic protective antigens.] Zh Mikrobiol Epidemiol Immunobiol2000;3: 47–51.Russian.
- Toporkov AV, Zadnova SP, Smirnova NI. [Comparative analysis of the major protective antigens production in Vibrio cholerae recombinant and producer strains of the classical biovar.] Zh Mikrobiol Epidemiol Immunobiol2005;1: 53–57.Russian.
- Zadnova SP, Toporkov AV, Smirnova NI. [Isolation and phenotyping of Vibrio cholerae strains with the enhanced production of main protective antigens.] Zh Mikrobiol Epidemiol Immunobiol2001;2: 3–6.Russian.
- Dzhaparidze MN, Naumov AV, Gromova OV et al. [The use of a new strain of Vibrio cholerae O139 as a producer of an enteric chemical vaccine.] Zh Mikrobiol Epidemiol Immunobiol1996;2: 52–55.Russian.
- Fedorova VA, Tereshkina NE, Gromova OV et al. [New methods for the control of the synthesis of immunogens during the production of the chemical vaccine against cholera caused by Vibrio cholerae O139.] Biotecnology1999;2: 82–88.Russian.
- Fedorova VA, Devdariani ZL, Gromova OV et al. [Some immunochemical and immunobiological properties of Vibrio cholerae serovar 0139 capsule antigen.] Mol Gen Mikrobiol Virusol1997;3: 18–20.Russian.
- Markov EIu, Urbanovich LIa, Golubinski1˘ EP et al. [The outer membranes of Vibrio cholerae as a potential component in a chemical vaccine.] Zh Mikrobiol Epidemiol Immunobiol1995;Suppl 2: 86–89.Russian.
- Eko FO, Schukovskaya T, Lotzmanova EY et al.Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 2003;21: 3663–3674.
- Nisjegorodsev SA.The development of new technology of O-antigen for the production of cholera bivalent chemical tableted vaccine. PhD thesis, Saratov State Agrarian University, Saratov, Russia, 2003.
- Ulianov AS.Improving the production of cholera bivalent chemical tableted vaccine. PhD thesis, Saratov State Agrarian University, Saratov, Russia, 2011.
- Mott TM, Estes DM, Torres AG.Recent progress in the development of vaccines for glanders and melioidosis.In: Feodorova VA, Motin VL (eds.) Vaccines against bacterial biothreat pathogens.Kerala: Research Signpost, 2011: 93–110.
- Zhukov SI, Demyan OB, Avrorova IV et al. [Comparative effectiveness integrated liposomal antigenic drugs immunization experimental melioidosis.] Infect Immun2012;2: 102.Russian.
- Kravchenko TB, Platonov ME, Vahrameeva GM et al. [Cloning and expression of protective antigens of Mycobacterium tuberculosis Ag85B and ESAT-6 in Francisella tularensis 15/10.] Biochemistry (Mosc)2007;72: 735–743.Russian.
- Pavlov VM, Mokrievich AN, Noskov AN et al. [Tularemia vaccine strain is a potential vector.] Vestn Ross Akad Med Nauk1997;6: 30–32.Russian.
- Pavlov VM.Methodology and results of molecular genetic study vaccine strain Francisella tularensis. DSc thesis, State Research Center for Applied Microbiology & Biotechnology, Obolensk, Russia, 2011.
- Mikshis NI, Popova PIu, Kudriavtseva OM et al. [Immunogenicity of protective antigen extracted from asporogenic recombinant strain Bacillus anthracis.] Zh Mikrobiol Epidemiol Immunobiol2011;1: 44–48.Russian.
- Mikshis NI, Kudriavtseva OM, Bolothikova MF et al. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis.] Mol Gen Mikrobiol Virusol2007;3: 15–21.Russian.
- Choose new content alerts to be informed about new research of interest to you
- Easy remote access to your institution's subscriptions on any device, from any location
- Save your searches and schedule alerts to send you new results
- Export your search results into a .csv file to support your research